In a filing, Eton Pharmaceuticals Inc revealed its President & CEO BRYNJELSEN SEAN unloaded Company’s shares for reported $1.23 million on Jun 03 ’25. In the deal valued at $17.51 per share,70,000 shares were sold. As a result of this transaction, BRYNJELSEN SEAN now holds 3,013,513 shares worth roughly $47.34 million.
Then, BRYNJELSEN SEAN sold 70,000 shares, generating $1,190,000 in total proceeds. Upon selling the shares at $17.00, the President & CEO now owns 2,943,513 shares.
Before that, BRYNJELSEN SEAN sold 70,000 shares. Eton Pharmaceuticals Inc shares valued at $1,176,700 were divested by the President & CEO at a price of $16.81 per share. As a result of the transaction, BRYNJELSEN SEAN now holds 2,873,513 shares, worth roughly $45.14 million.
H.C. Wainwright reiterated its Eton Pharmaceuticals Inc [ETON] rating to a Buy in a research note published on January 23, 2025; the price target was $33. A number of analysts have revised their coverage, including B. Riley Securities’s analysts, who began to cover the stock in early January with a ‘”a Buy”‘ rating. H.C. Wainwright also remained covering ETON and reiterated its “Buy” recommendation on January 06, 2025.
Price Performance Review of ETON
On Tuesday, Eton Pharmaceuticals Inc [NASDAQ:ETON] saw its stock fall -0.88% to $15.71. Over the last five days, the stock has lost -9.09%. Eton Pharmaceuticals Inc shares have risen nearly 17.94% since the year began. Nevertheless, the stocks have risen 331.59% over the past one year.
How much short interest is there in Eton Pharmaceuticals Inc?
A steep rise in short interest was recorded in Eton Pharmaceuticals Inc stocks on 2025-05-15, growing by 0.19 million shares to a total of 0.59 million shares. Yahoo Finance data shows the prior-month short interest on 2025-04-15 was 0.4 million shares. There was a rise of 31.7%, which implies that there is a positive sentiment for the stock.
The most recent change occurred on May 06, 2024 when Craig Hallum began covering the stock and recommended ‘”a Buy”‘ rating along with a $8 price target.
